INCR
InterCure Ltd.
There isn't enough reported data to score INCR yet.
INCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
INCR's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
INCR PE Valuation
INCR has no meaningful PE right now: it lost money over the past year.
INCR Forward outlook
There aren't enough analyst estimates for INCR to show an outlook.
INCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.32 | -$0.18 |
| Q4 2023 | -$2.14 | -238% |
| Q4 2022 | $1.55 | +812% |
| Q4 2021 | $0.17 | +$2.61 |
| Q4 2020 | -$2.44 | -$2.25 |
| Q3 2020 | -$3.93 | -1059% |
| Q2 2020 | -$5.04 | -567% |
| Q1 2020 | -$5.75 | -459% |
INCR is still losing money, but far less than before: $2.32 per share over the past year, against $5.75 at its worst in early 2020.
INCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $75M | -33% |
| Q4 2023 | $111.7M | -8.5% |
| Q4 2022 | $122.1M | +77% |
| Q4 2021 | $69M | +711% |
| Q4 2020 | $8.5M | +1382% |
| Q3 2020 | $7.1M | +766% |
| Q2 2020 | $3.5M | +303% |
| Q1 2020 | $1.3M | +147% |
INCR's revenue has grown year over year for 12 quarters in a row: $75M last quarter, up 782% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -28% | -56 points |
| Q4 2023 | -12% | -22 points |
| Q4 2022 | 13% | +21 points |
| Q4 2021 | 13% | +1125 points |
| Q4 2020 | 28% | +765 points |
| Q3 2020 | 11% | +566 points |
| Q2 2020 | -7.6% | +363 points |
| Q1 2020 | -1113% | -3300 points |
INCR's operating margin was −28% last quarter, down 56 points from the same quarter a year ago.
INCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$22.4M | -$4.7M |
| Q4 2023 | -$17.7M | -278% |
| Q4 2022 | $9.9M | +187% |
| Q4 2021 | $3.5M | +136% |
| Q4 2020 | $1.5M | -84% |
| Q3 2020 | $525.2K | +$5.5M |
| Q2 2020 | -$2.9M | +$1.4M |
| Q1 2020 | -$3.1M | -$2.3M |
INCR has burned cash in most quarters: −$27M over the past year, against −$4M the year before.
INCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.1x | Net Cash |
| Q4 2021 | -3.2x | Net Cash |
| Q4 2020 | -3.7x | Net Cash |
| Q3 2019 | -0.4x | Net Cash |
| Q2 2019 | -2.1x | Net Cash |
| Q1 2019 | 0.3x | Very low |
| Q4 2016 | -0.4x | Net Cash |
INCR has more cash than debt.
INCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 13.5 | Oversold |
INCR's weekly RSI is 42 (neutral) and its Stochastic is 14 (oversold).
INCR PE vs Healthcare Sector
| Metric | INCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INCR has no meaningful PE right now: it lost money over the past year.
INCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 12% below |
| 20 week MA | $4.83 | 18% below |
| 50 week MA | $4.77 | 17% below |
| 100 week MA | $6.21 | 36% below |
| 200 week MA | $8.06 | 51% below |
INCR is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
INCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.45 | $6.00 | +10% |
| 2021 | $6.00 | $36.0 | +500% |
| 2022 | $36.0 | $19.2 | -47% |
| 2023 | $19.2 | $6.45 | -66% |
| 2024 | $6.45 | $8.15 | +26% |
| 2025 | $8.15 | $5.65 | -31% |
| 2026 YTD | $5.65 | $3.98 | -30% |
INCR's yearly returns have swung widely, from +500% in 2021 to −66% in 2023. It's down 30% so far in 2026.